维利帕尼联合替莫唑胺在非血液系统恶性肿瘤中的临床药代动力学与物质平衡
本研究为开放标签、剂量递增的I期试验,纳入42例非血液系统恶性肿瘤受试者,评估维利帕尼单用及联用替莫唑胺的药代动力学与物质平衡。结果显示维利帕尼在10-80 mg每日两次范围内呈线性药代动力学,原形及M8代谢物尿回收率分别为73±18%和90±22%,与替莫唑胺联用无药代相互作用。
要点
- 维利帕尼10-80 mg每日两次呈现线性药代动力学。
- 维利帕尼主要经肾排泄,原形尿回收率73±18%。
- 维利帕尼与替莫唑胺联用未见药代相互作用。
核心结论
- 维利帕尼为BCS 1类化合物,吸收不低于90%,口服生物利用度至少73%。
- 维利帕尼主要经肾排泄,在10-80 mg每日两次范围内呈线性药代动力学。
- 维利帕尼与替莫唑胺联合给药时未观察到药代动力学相互作用。
研究设计与样本
- 开放标签、剂量递增的I期研究,纳入42例非血液系统恶性肿瘤受试者。
- 维利帕尼口服10-80 mg每日两次,第1-7天给药;替莫唑胺口服150-200 mg/m2每日一次,每28天周期第1-5天给药。
- 测定维利帕尼、其M8代谢物及替莫唑胺的药代动力学,以及原形维利帕尼和M8代谢物的尿排泄。
主要发现
- 维利帕尼10-80 mg每日两次剂量范围内,平均Cmax和AUC6呈剂量比例增加。
- 第1周期第6天12小时给药间期内,原形维利帕尼及原形加M8代谢物的尿回收率分别为73±18%和90±22%。
- 维利帕尼与替莫唑胺同时给药时,两者药代暴露量均未受影响。
关键数值与推荐
- 维利帕尼为BCS 1类化合物,吸收不低于90%,口服生物利用度至少73%。
- 维利帕尼10-80 mg每日两次范围内呈线性药代动力学。
- 维利帕尼与替莫唑胺联用无药代动力学相互作用。
临床怎么用
- 维利帕尼主要经肾排泄,临床用药时需关注肾功能对暴露量的潜在影响。
- 维利帕尼与替莫唑胺联用时无需基于药代相互作用调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Veliparib is an orally active potent poly(ADP-ribose) polymerase (PARP) inhibitor currently in phase III clinical trials in solid tumors. This phase I study evaluated the pharmacokinetics and mass balance of veliparib administered alone and in combination with temozolomide, and assessed any potential pharmacokinetic drug-drug interaction between veliparib and temozolomide. METHODS: This was an open-label, dose-escalation study of veliparib in combination with temozolomide in 42 subjects with nonhematologic malignancies. Veliparib was administered orally at doses ranging from 10 to 80 mg twice daily on days 1-7, and temozolomide was administered orally at 150-200 mg/m2 once daily on days 1-5 of each 28-day cycle. The pharmacokinetics of veliparib, its M8 metabolite, and temozolomide, as well as urinary excretion of unchanged veliparib and its M8 metabolite, were determined. RESULTS: Mean veliparib maximum observed plasma concentration (C max) and area under the plasma concentration-time curve for the first 6 h postdose (AUC6) values increased dose proportionally in the veliparib 10-80 mg twice-daily dose range. The urinary recovery of veliparib dose as the unchanged parent compound alone and together with the M8 metabolite was 73 ± 18 and 90 ± 22%, respectively, over a 12-h dosing interval on day 6 of Cycle 1. Veliparib and temozolomide pharmacokinetic exposures were not affected when administered together. CONCLUSIONS: Veliparib is a Biopharmaceutical Classification System (BCS) Class 1 compound, with no less than 90% of the dose absorbed and an oral bioavailability of at least 73%. Veliparib is primarily eliminated by renal excretion. Veliparib exhibited linear pharmacokinetics in the 10-80 mg twice-daily dose range. No pharmacokinetic interaction was observed when veliparib and temozolomide were administered together. CLINICAL TRIAL REGISTRATION NUMBER: NCT00526617.
引用
- Nuthalapati S, Munasinghe W, Giranda V, et al. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clin Pharmacokinet. 2018. PMID: 28497258. doi:10.1007/s40262-017-0547-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。